Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.

MLA

Bagley, Stephen J., et al. “Repeated Peripheral Infusions of Anti-EGFRvIII CAR T Cells in Combination with Pembrolizumab Show No Efficacy in Glioblastoma: A Phase 1 Trial.” Nature Cancer, vol. 5, no. 3, Mar. 2024, pp. 517–31. EBSCOhost, https://doi.org/10.1038/s43018-023-00709-6.

APA

Bagley, S. J., Binder, Z. A., Lamrani, L., Marinari, E., Desai, A. S., Nasrallah, M. P., Maloney, E., Brem, S., Lustig, R. A., Kurtz, G., Alonso-Basanta, M., Bonté, P.-E., Goudot, C., Richer, W., Piaggio, E., Kothari, S., Guyonnet, L., Guerin, C. L., Waterfall, J. J., … O’Rourke, D. M. (2024). Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nature Cancer, 5(3), 517–531. https://doi.org/10.1038/s43018-023-00709-6

Chicago

Bagley, Stephen J, Zev A Binder, Lamia Lamrani, Eliana Marinari, Arati S Desai, MacLean P Nasrallah, Eileen Maloney, et al. 2024. “Repeated Peripheral Infusions of Anti-EGFRvIII CAR T Cells in Combination with Pembrolizumab Show No Efficacy in Glioblastoma: A Phase 1 Trial.” Nature Cancer 5 (3): 517–31. doi:10.1038/s43018-023-00709-6.